CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0162
Issued: 2026-09-08

PRODUCT IDENTIFICATION

PRODUCT NAD+ 500mg	SKU / INTERNAL CODE CRF-2026-0162	PRESENTATION Lyophilised powder, 500mg vial
BATCH NUMBER CRF-2026-0162	SAMPLE RECEIVED 2026-09-01	PRODUCTION DATE 2026-08-27
ANALYSIS DATE 2026-09-06	EXPIRY / RETEST DATE 2028-09-06	MOLECULAR FORMULA C21H27N7O14P2
MOLECULAR WEIGHT (G/MOL) 663.43	CAS 53-84-9	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

Recorded methods: HPLC-UV · LC-MS · KF water content · Residual solvents (GC)

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.6%	PASS
Identity (LC-MS)	663.4 ±2%	Obs: 663.4 [M+H]+	PASS
Quantity found	95.0–105.0%	497.0 mg (99.4%)	PASS
Endotoxin	<1.0 EU/mg	N/A	N/A
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Category: Longevity. Sample conforms to label claim and Gold panel acceptance criteria.

ANALYTICAL METHOD

INSTRUMENT Agilent 1260	COLUMN C18 4.6×150mm	COLUMN TEMPERATURE 30°C
MOBILE PHASE A 0.1% Formic Acid	MOBILE PHASE B MeOH	FLOW RATE 1.0 mL/min
	INJECTION VOLUME 10 µL	SAMPLE CONCENTRATION 1.0 mg/mL

RETENTION TIME (MAIN PEAK)
4.8 min

crafa

CRAFA